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Abstract
Background: Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are systemic autoimmune connective
tissue diseases that share overlapping clinico-pathological features. It is highly probable that there is an overlap in
epigenetic landscapes of both diseases. This study aimed to identify similarities in DNA methylation changes in genes
involved in SLE and SSc. Global DNA methylation and twelve genes selected on the basis of their involvement in
inflammation, autoimmunity and/or fibrosis were analyzed using PCR arrays in three groups, each of 30 Black South
Africans with SLE and SSc, plus 40 healthy control subjects.
Results: Global methylation in both diseases was significantly lower (<25 %) than in healthy subjects (>30 %, p =
0.0000001). In comparison to healthy controls, a similar gene-specific methylation pattern was observed in both SLE
and SSc. Three genes, namely; PRF1, ITGAL and FOXP3 were consistently hypermethylated while CDKN2A and CD70
were hypomethylated in both diseases. The other genes (SOCS1, CTGF, THY1, CXCR4, MT1-G, FLI1, and DNMT1) were
generally hypomethylated in SLE whereas they were neither hyper- nor hypo-methylated in SSc.
Conclusions: SSc and SLE patients have a higher global hypomethylation than healthy subjects with specific genes
being hypomethylated and others hypermethylated. The majority of genes studied were hypomethylated in SLE
compared to SSc. In addition to the commonly known hypomethylated genes in SLE and SSc, there are other
hypomethylated genes (such as MT-1G and THY-1) that have not previously been investigated in SLE and SSc though
are known to be hypermethylated in cancer.
Keywords: Methylation, Peripheral blood, Genomic DNA, Systemic lupus erythematosus, Systemic sclerosis,
Autoimmunity, Methyl qPCR arrays
Background
Systemic lupus erythematosus (SLE, lupus) and systemic
sclerosis (SSc, scleroderma) are both autoimmune con-
nective tissue diseases associated with autoantibody pro-
duction. In SLE, inflammation often affecting more than
one organ is the outstanding pathological feature [1],
whereas in SSc immune activation results mainly in fi-
brosis of the skin and internal organs, and damage of
small blood vessels [2,3]. Although the exact genetic
causes of both SSc and SLE are still unknown, the envir-
onmental influence reflected by the epigenetic mecha-
nisms, with DNA methylation changes in particular, are
generally considered as key players in the onset and pro-
gression of both diseases [1,4,5]. The concordance of
these conditions in monozygotic twins indicates that epi-
genetic factors, mediated by environmental factors, may
have a role to play [4,6,7].
Epigenetic mechanisms, one example of which is DNA
methylation, are vital for the development and function
of the immune system. DNA methylation is important in
the regulation of inflammatory genes [8]. Hypermethyla-
tion of promoter regions of genes is typically associated
with transcriptional silencing while hypomethylation facili-
tates gene expression. In autoimmunity, aberrant DNA
methylation profiles in genes encoding metalloproteinases,
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proinflammatory cytokines and chemokines, all processes
that regulate inflammation have been reported. Al-
though the roles and interactions of abnormal DNA
methylation in relation to inflammation and immunity
are not yet clear, evidence suggests that key mediators
of inflammation-induced DNA methylation changes are
oxidative stress and the increased pro-inflammatory cy-
tokines [9]. Endogenous triggers such as antigens re-
leased from dying cells are recognized as the main
stimulus to abnormal production of type I interferon
(IFN-I) resulting in chronic inflammation in SLE and
SSc, and perhaps other autoimmune diseases [10]. The
clearance of apoptotic cells is impaired in SLE and SSc,
providing a potential continuous source of endogenous
antigen. Proper control of DNA methylation is maintained
by the DNA methyltransferases (DNMTs), and it appears
that persistent exposure to pro-inflammatory cytokines
can contribute to DNA hypomethylation through de-
creased expression of DNA methyltransferase (DNMT)
[9,11]. On the other hand, overexpression of the de novo
methyltransferases is implicated in the establishment of
gene-specific hypermethylation [12-14]. An illustration as
to how methylation of gene promoters by DNMT1 leads
to gene silencing, while its inhibition leads to hypomethy-
lation is shown in Fig. 1.
Accumulating evidence indicates that abnormal DNA
hypomethylation and expression of methylation-related
genes in CD4+ T cells are an important epigenetic hall-
mark associated with SLE and SSc [15-17]. This is
accounted for by the fact that DNMT1 expression and
enzymatic activity is reduced in SLE and SSc, and given
the high prevalence of inflammation and oxidative stress
in both conditions [9,15]. Several classic methylation-
sensitive autoimmunity-related genes in SLE and SSc have
been identified that include CD11a (ITGAL), perforin
(PRF1), CD70 (TNFSF7), CD40 ligand (TNFSF5) and
PP2Acα [5,18]. Other top-ranked methylation-sensitive
autoimmunity-related genes known to be associated with
SSc include CTGF, FLI1 and DNMT [19,20]. In fact,
current epigenetic studies reveal a growing list of genes
dysregulated by altered DNA methylation in many auto-
immune diseases. The array of genes dysregulated by al-
tered DNA methylation thus provides an opportunity to
examine the patterns of inactivation of such genes among
different autoimmune diseases.
The aim of this study was to determine global DNA
methylation and gene-specific methylation of potentially
“overlapping” genes involved in either collagen synthesis,
the inflammatory response or tumour suppression, in
black African SLE and SSc patients using genomic DNA
from whole blood. The choice of whole blood over CD4+
T cells as study material in this work was based on the
consideration that SLE and SSc display many abnormal-
ities across all arms of the immune system, represented in
whole blood. In fact, SLE and SSc therapies attempting to
target specific components of the immune system have so
far not been successful, so much that broad-based im-
munosuppression still remains the mainstay in the treat-
ment of both conditions [21]. Also, it has been confirmed
that defects in epigenetic regulation of both CD4+ T cells
[22,23] and B-cells [24-26] are involved in both SLE and
SSc. Moreover, literature indicates that the total number
of B and T lymphocytes is significantly reduced in SLE
and SSc [27,28], a situation that is aggravated by the im-
munosuppression therapy. It has therefore become clear
that the global methylation landscape in these two diseases
Fig. 1 Short title: Role of DNMT1 in DNA methylation. Long title: Methylation of gene promoters by DNMT1 leads to gene silencing, while its
inhibition leads to hypomethylation. Modified from Zielske, [66]
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involves both T and B lymphocytes, hence the choice to
study global DNA methylation as opposed to methylation
of only CD4+ T cells as in many other studies. Also, the
great majority of patients in this study had been receiving
glucocorticoids and immunosuppressants at different
doses, and therefore it would have been unethical and not
practically viable to collect enough blood from them to be
able to study individual lymphocyte populations, hence
the use of whole blood.
Results
The clinical information for the study participants is
presented in Tables 1 and 2. The records of all SLE and
SSc patients enrolled in the study were retrospectively
reviewed. In the case of SLE, patients’ disease-related
symptoms reflecting disease severity such as skin and
musculoskeletal involvement, serositis, systemic vascu-
litis and kidney involvement were identified. The data
showed that these SLE patients fell into three phenotypic
subsets as follows; 30 % (7 of 30) made SLE1 group (skin
and musculoskeletal involvement); 57 % (17/30) formed
SLE2 (serositis, systemic vasculitis, with no kidney
involvement) and 13 % (4/30) made up SLE3 group
(glomerulonephritis). All SSc patients had positive anti-
nuclear autoantibodies (ANA) but only a few were posi-
tive for anti-centromere autoantibodies (ACA) and/or
anti-topoisomerase antibodies (ATA). The SLEDAI score
showed that SLE was either mild or moderate, with no
severe cases of the condition in the study group. In
addition, correlation of PGA score (not shown), SLEDAI
and methylation status, showed that the sicker the pa-
tient (increasing SLEDAI and PGA score), the greater
was the percentage of global hypomethylation as well as
more number of genes demethylated. The majority
(67 %, 20/30) of SLE patients also had discoid lupus ery-
thematosus (DLE), while 50 % of them tested positive
for the Coomb’s test.
The SSc and SLE groups exhibited significantly lower
global methylation levels, compared to the control group
(p < 0.000001) (Fig. 2). This is so despite the fact that
global hypomethylation was also observed even among
some of the healthy subjects. Further analysis of the in-
dividual genes, as shown in the heat map (Fig. 3), indi-
cates that the majority of genes included in the present
study were hypomethylated in the patient groups [9 of
12 (75 %) of genes] compared to the control group.
Conversely, three genes were hypermethylated in the pa-
tient groups, namely; PRF1, ITGAL and FOXP3. When
comparing the two patient groups to each other a sig-
nificantly differential methylation pattern was observed
amongst the individual genes with the exception of
ITGAL and PRF1 which were consistently hypermethy-
lated in both diseases while CDKN2A and CD70 were
consistently hypomethylated. Fig. 3 also shows a uniform
methylation distribution among SLE patients, whereas
SSc patients seem to split into several groups, which
could perhaps indicate the different disease grades. All
the other genes analyzed (SOCS1, CTGF, THY1, CXCR4,
MT1-G, FLI1, and DNMT1) were generally hypomethy-
lated in SLE whereas they were neither hypermethylated
nor hypomethylated in most SSc patients.
Discussion
Our findings confirm that DNA methylation is globally
reduced in SLE and SSc, and that there is abnormal ex-
pression of methylation-related genes [15]. Also, increas-
ing SLEDAI and PGA scores were indicative of
increasing number of genes demethylated in SLE and
worsening of the disease in the patient. In SSc there was
no difference observed in both global and gene-specific
DNA methylation between diffuse and limited sclerosis
patients, even though subset-specific DNA methylation
abnormalities have been reported between the two dis-
ease subtypes [29]. In fact both were equally hypomethy-
lated (about 18 % DNA methylation). This highlights the
robustness of genome-wide analyses over analysis of a
few candidate genes in this study. Global hypomethyla-
tion was also observed even among some of the healthy
subjects (Fig. 2). An important factor to consider in this
situation is the well known fact that there are differences
in methylation status of individuals which is to some ex-
tent controlled by certain host and lifestyle characteris-
tics such as age, smoking, alcohol drinking, diet and
health history [30-32]. These factors were controlled to
a very limited extend in this study. Fig. 3 also shows that
there are some patients that fall within both SLE and
SSc groups. Serology tests (ANA positivity) also confirm
overlap in both conditions (Table 3). This is not surpris-
ing since it is known that both SSc and SLE show an
overlap of symptoms and in many instances there are
patients who develop both conditions [17,33].
Table 1 Demographics for study participants
Study subjects Controls SLE SSc
n Age range (mean) yrs n Age range (mean) yrs n Age range (mean) yrs
Male 12 20-51 (35) 5 22-66 (45) 3 48-56 (51)
Female 28 22-53 (36) 25 22-63 (42) 27 32-60 (47)
Total 40 20-53 (38) 30 22-66 (42) 30 32-60 (48)
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In this study specific genes that were found to be
hypomethylated include CTGF, CXCR4, CD70, MT-1G,
THY1, CDKN2A, SOCS1, FLI1 and DNMT1. CTGF is
known to be constitutively upregulated in SSc and has
been hypothesized to be a key mediator of pulmonary fi-
brosis due to its overexpression which correlates well
with severity of lung fibrosis frequently observed in this
disease [12]. Therefore, the observed CTGF hypomethy-
lation in this study could well indicate the progression of
both SLE and SSc to a stage of pulmonary involvement.
In fact, the indication of pulmonary involvement, which
is the presence of interstitial lung disease (ILD), was ob-
served in 17 % (5/30) of the SSc patients. CXCR4 has been
found prominently, particularly in various leukocyte sub-
sets of the skin and kidney of SLE patients, and has been
shown to mediate chemotaxis of T-lymphocytes [34].
Hypomethylation of this gene in the study could also indi-
cate its overexpression and hence progression of disease
in these patients.
Hypermethylation results in suppression of PRF1,
ITGAL and FOXP3 and this explains why these three
genes may have a role in the immunopathogenesis of
Table 2 Lupus and scleroderma disease presentation according to autoantibody serology, manifestations and tests
Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc)

























(n = 22) 73 %
13 6 5 n/a
ANA positive
(n = 29) 97 %
20 3 0 6 ACA positive
(n = 6) 20 %
3 2 1 n/a
DLE positive
(n = 19) 63 %
15 2 0 3 ATA positive
(n = 2) 7 %
2 0 0 n/a
Coombs’ test
positive
(n = 14) 47 %
9 3 0 3 ILD (n = 10)
33 %
6 1 3 n/a
Abbreviations: ACA, anticentromere autoantibody; ANA, anti-nuclear antibodies; ATA, Antitopoisomerase antibodies; Coombs’ test, detects presence of antibodies that act
against the surface of red blood cells, indicates haemolytic anaemia; DLE, Discoid lupus erythematosus; ILD, interstitial lung disease, indicator of direct pulmonary
involvement, and leading cause of death; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; UCTD, undifferentiated connective tissue
disease; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; n/a, results not available.
Fig. 2 Short title: Global methylation in peripheral blood of SLE, SSc and healthy (C) subjects. A significant difference in global methylation
between the study groups is indicated by the p-values. Long Title: Analysis of global methylation levels in peripheral blood of SLE, SSc and healthy
control subjects (triplicate measurements). The dot plot shows a significant difference in global methylation between the patients and healthy
subjects, which is also indicated by the p-values. However, SLE and SSc patients were not significantly different from each other although there
was a trend towards lower values in the SSc group compared to the SLE group
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SSc and SLE. For example, it has been demonstrated
that the epigenetic control of FOXP3 for effective func-
tion of T-regulatory cells dictates the requirement of a
hypomethylated FOXP3 promoter [35]. However, the op-
posite is seen in the case of these SLE and SSc patients,
and this situation is known to correlate highly with pa-
rameters of disease severity and the high incidence of
SLE and SSc and other autoimmune diseases.
Many studies report hypomethylation in promoter re-
gions of PRF1 and ITGAL with consequent overexpres-
sion of these genes in SLE. It is therefore tempting to
attribute the observed hypermethylation of these two
genes in this study to technical/experimental errors.
However, further survey of literature indicates that there
are high levels of free polyamines in SLE and that poly-
amines not only cause SLE, but they are also important
in sustaining the disease [36,37]. These increased poly-
amine concentrations result in enhanced methylation of
the ITGAL promoter and increased DNMT1 activity
[38]. Hypermethylation of the ITGAL promoter region
has also been observed in CD4+ T cells from other auto-
immune diseases [39]. So, we suggest that even though
hypomethylated ITGAL and PRF1 promoters are mostly
reported as characteristic of SLE, this is not always the
case as was seen in this study, and this situation may
represent the co-occurrence of other autoimmune con-
ditions such as diabetes and cancer, with SLE and SSc.
The opposite from what is reported in other studies is
also observed for several of these genes in this study. For
example, hypermethylation of both FLI1 in SSc and
SOCS1 in SLE was not observed in our study even
though hypermethylation of promoter regions of both
genes has been previously implicated in the pathophysi-
ology of SSc and SLE, respectively [40-42]. However,
FLI-1 overexpression, probably as a result of promoter
hypomethylation, has been detected in various types of
cancer and other diseases [43]. Most importantly, it has
been reported that in lupus-prone mice Fli1 expression
fails to become down-regulated likely due to aberrant
transcriptional regulation [44]. Also, it is reported that
increasing SOCS1 expression by cells may be useful as a
strategy to block CD8(+) T cell-mediated autoimmunity
and to more generally prevent cytokine-dependent tissue
destruction in inflammatory diseases [45]. The observed
hypomethylation of FLI1 and SOCS1 could therefore
imply that both genes were overexpressed in these pa-
tients for the reasons already mentioned. Similarly, other
studies have reported that CDKN2A and DNMT1 gene
promoters are hypermethylated in DNA derived from
plasma and blood cells of patients with SLE, whereas the
opposite was observed in this study [46,47]. Increased
expression of CDKN2A has been shown to be as a result
of promoter demethylation [48,49] and recently it has
been shown that presence of up-regulated CDKN2A ex-
pression, promotes apoptosis and cellular senescence of
bone marrow-derived mesenchymal stem cells observed
in SLE patients [50]. In the same way, Liu et al., [51] re-
ported that expression of DNMT1 mRNA was signifi-
cantly increased in SLE, whereas other studies [52]
describe the opposite. As mentioned above high levels of
natural polyamines in SLE result in increased DNMT1
activity, and this is probably due to a hypomethylated
promoter region as was observed in this study.
The other genes (MT-1G and THY1) which were
found to be hypomethylated in this study have not been
previously investigated in SSc and SLE, though are
Fig. 3 Short title: Comparison of gene-specific methylation in lupus (SLE), scleroderma (SSc) and healthy subjects (C). Long title: Heat map showing
distribution of methylation among the 12 genes analyzed in lupus (SLE) and scleroderma (SSc) patients in comparison to healthy controls (C)
Table 3 Analysis of variance was conducted on the global
methylation results with disease group as the factor variable,
and the results were verified with Bartlett’s test. A Bonferroni
correction shows that the SLE and SSc groups were significantly
different from the controls but not significantly different from
each other, although there was a trend towards lower values in




Mean Standard deviation (SD) Range
Controls 33.9 11 11-53
SLE 22.2 5 15 – 33
SSc 17.7 5 3.8 - 24
Study groups
comparison
(mean difference) P value
Controls SLE
SLE (−11) p = 0.00 -
SSc (− 16) p = 0.00 (−4) p = 0.068
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known to be hypermethylated in cancer [16,53,54]. Fi-
nally, there are significant methylation differences in in-
dividual genes between the two patient groups, and
though the methylation status of some may not conform
to the majority of literature reports this does not defy
what is already known about the role of these genes in
SLE and SSc, which is their involvement in inflamma-
tion, autoimmunity and/or fibrosis. Moreover, Wiley et
al., [55] suggest that variation in epigenetic changes may
play a critical role in the different manifestations of the
disease observed among ethnic groups. Kozłowska et al.,
[56] also suggest that exposure to unique environmental
factors as well as genetic variation associated with the
special racial properties of the examined groups both
contributing to SLE and SSc in this population could
have resulted in these deviations. It would be interesting
to investigate the influence of ethnicity and/or race on
the epigenetics of these genes to complete our study
[57]. Hughes and Sawalha [58] suggest that the fact that
patients experience periods of calm punctuated by dis-
ease flare-ups in SLE and SSc is as a result of epigenetic
states which vary with time and between cell types, and
if this is the case these results could be highly influenced
by the disease activity state at the time of sampling. It
should also be noted that since blood samples were col-
lected only once, at commencement of the study, it was
not possible to determine the effect of immunosuppres-
sive treatment on methylation in the study subjects. As a
result, neither global DNA hypomethylation nor changes
in gene-specific DNA methylation patterns were
accounted for by the type of medication the patients
were taking. However, certain studies have reported that
the antiproliferative drugs commonly used to treat SLE
do not have any effect on DNA methylation [59-61], and
therefore it is believed that changes in the methylation
status of these patients are unlikely to be the result of
immunosuppressive treatment. On the other hand, other
studies show that systemic steroid use is associated with
variable DNA methylation patterns throughout the gen-
ome [23,62], which could have been missed due to the
limited number of genes investigated in this study.
Due to the small number of genes analysed it was not
possible to neither reliably distinguish SSc from SLE,
nor clearly indicate the overlap genes. It should also be
noted that inconsistencies in literature on methylation/
disease relationship are often attributable to the meas-
urement method; hence the need for standardization of
methods for DNA methylation analysis if further studies
are undertaken. Therefore, one could say that the
current data strongly demonstrate the need for investi-
gation on a larger scale, with many subjects and many
genes as is possible with the use of microarrays in
genome-wide association studies. May be these epigen-
etic changes can be used as biomarkers of these diseases
or their severity. It is also worth noting that the overall
picture regarding epigenetic control of autoimmunity
still remains elusive. However, evidence points to meta-
bolic control as the central mechanism underlying aber-
rant gene expression leading to dysregulation of the
immune system, especially in SLE [63]. Apparently mito-
chondrial dysfunction in T cells as a result of oxidative
stress is the driver of chronic inflammation which in
turn triggers autoimmunity in SLE. It is therefore pos-
sible that the metabolic profile could actually be the de-
termining factor with regard to the differences between
the different autoimmune diseases and their variations,
as well as between the healthy and the sick.
Conclusion
Notwithstanding the limitations of the study, this work
confirms that SSc and SLE patients have a higher global
hypomethylation than healthy subjects. As far as the au-
thors are aware, this is the first report of a comparison
of DNA methylation of genes affected in both SLE and
SSc. Even though it is generally accepted that in addition
to genetic dysregulation epigenetic modification of genes
is responsible for both diseases the origin of epigenetic
similarity of their symptoms has never been investigated.
Moreover, this is the first study in which DNA methyla-
tion analysis of SLE and SSc has been done in the black
African population. The study has shown that in addition
to the commonly known hypomethylated genes in SLE
and SSc, there are other hypomethylated genes that have
not previously been investigated in both conditions, even
though they are known to be hypermethylated in cancer.
These genes are involved in either collagen synthesis, in-
flammatory response or have tumour suppressor activities,
and their dysregulation could contribute to inflammation/
fibrosis/tumourigenesis processes characteristic of SLE
and SSc. It is obvious that there are several emergent
phenotypes in SLE and SSc, likely as a result of their inter-
action over time which may in turn be influenced by co-
occurrence with other diseases, unique environmental
exposures or ethnicity/race, and it is not as yet possible to
understand clearly delineation of these various compo-
nents. Perhaps, it is more studies like this that could lead
to identification of critical genes common to both SLE
and SSc, which could possibly enable researchers to eluci-
date the aetiology of both diseases and to design appropri-
ate gene targeted therapy.
Methods
Patients
This study was approved by the Ethics Committee for
Research on Human Subjects of both the University of
the Witwatersrand (Johannesburg, South Africa) and the
South African National Blood Transfusion Services
(SANBS). A total of 100 adult Black South African
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participants (18 years or older) comprising 30 patients each
of SLE and SSc, and 40 healthy controls were recruited for
the study. These SSc and SLE patients each fulfilling the
American College of Rheumatology (ACR) criteria for SSc
or SLE [64, 65] were recruited from the Connective Tis-
sue Diseases Clinic, Chris Hani-Baragwanath Hospital
(Johannesburg, South Africa). The healthy individuals
were volunteer blood donors recruited during a blood
drive by the SANBS (Johannesburg, South Africa).
Serology tests and disease activity
All patients underwent baseline investigations for haem-
atological and biochemical parameters, chest radiograph
and electrocardiogram. Autoantibodies (e.g. ANA, anti-
dsDNA, ATA) were detected by indirect immunofluores-
cence test. Various manifestations were categorized after
detailed clinical examination and laboratory investiga-
tions (Table 3). Disease activity was assessed by the
physician global assessment (PGA) score as well as the
SLE Disease Activity Index (SLEDAI).
Sample collection and DNA preparation
After obtaining written informed consent from all blood
donors, 5 ml samples of peripheral blood were collected
in EDTA tubes. Genomic DNA (gDNA) from whole
blood was isolated using GenElute mammalian DNA ex-
traction kit (Sigma-Aldrich, catalogue no. G1N70). The
isolated DNA was quantified using the Nanodrop 2000C
spectrophotometer (Thermoscientific) and thereafter
stored at −20 °C until use.
Quantification of global DNA methylation
Imprint™ Methylated DNA kit (Sigma-Aldrich, catalogue
No. MDQ1) was used to determine global DNA methyla-
tion shifts and triplicate values were measured. This is an
ELISA-based procedure consisting of four steps. Up to
200 ng of purified DNA is bound to the wells of the assay
strip. The methylated DNA is detected using the capture
and detection antibodies, and then quantified colorimetri-
cally. The amount of methylated DNA present in the sam-
ple is proportional to the absorbance measured and is
expressed as a percentage of the provided DNA control.
Gene-specific DNA methylation analysis
The panel of genes profiled consisted of twelve genes,
namely; ITGAL, PRF1, SOCS1, CTGF, CXCR4, THY1,
MT1G, FLI1, P16INK4, DNMT1, FOXP3, and CD70. PCR
Array analysis was performed using the EpiTect Methyl
PCR Arrays technology (SABiosciences) on a 7300 Ap-
plied Biosystems real-time PCR instrument.
Data analysis
The methylation qPCR Arrays data was analyzed using
an integrated Excel-based template provided by the
Methyl Screen™ technology (SABiosciences). The tem-
plate automatically performs all ΔCt based calculations
from the raw threshold cycle (Ct) values to determine
gene specific DNA methylation status, and then normal-
izes the Ct values of both digests with the mock diges-
tion values to calculate and report the percentage of the
DNA that is methylated and unmethylated.
Statistical analysis
The methylation results data was captured in standard
data entry software STATA®. Analysis was carried out
using both Kruskal Wallis test and Mann–Whitney U-test.
Analysis of variance was conducted and Bartlett’s test was
used to confirm observed variances. A Bonferroni correc-
tion was used to compare the individual groups. P values
were generated from individual t-tests and differences were
considered significant at a p value <0.05.
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